Plasma amyloid-β oligomers and soluble tumor necrosis factor receptors as potential biomarkers of AD

Current Alzheimer Research

Volumn 11, Issue 4, 2014, Pages 325-331

  Zhang, Jinbiao ^a,b,c   Peng, Mao ^a,b   Jia, Jianping ^a,b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c Weihai Municipal Hospital   (China)

Author keywords

Alzheimer's disease; Amyloid beta oligomers; Biomarker; ELISA; Soluble tumor necrosis factor receptor

Indexed keywords

AMYLOID BETA OLIGOMER; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; OLIGOMER; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG; APOLIPOPROTEIN E; BIOLOGICAL MARKER; TUMOR NECROSIS FACTOR RECEPTOR;

AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; BLOOD; GENETICS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MILD COGNITIVE IMPAIRMENT; RECEPTORS, TUMOR NECROSIS FACTOR; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84904459652     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205011666140317103222     Document Type: Article

References (43)

1. Holtzman DM, Morris JC, Goate AM. Alzheimer's disease: the challenge of the second century. Sci Transl Med 3: 77sr1 (2011).
2. De Strooper B. Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. Physiol Rev 90: 465-94 (2010).
3. Heneka MT, O'Banion MK, Terwel D, Kummer MP. Neuroinflammatory processes in Alzheimer's disease. J Neural Transm 117: 919-47 (2010).
4. Mrak RE, Griffin WS. Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging 26: 349-54 (2005).
5. Sastre M, Walter J, Gentleman SM. Interactions between APP secretases and inflammatory mediators. J Neuroinflammation 5: 25 (2008).
6. Caroli A, Frisoni GB. Quantitative evaluation of Alzheimer's disease. Expert Rev Med Devices 6: 569-88 (2009).
7. Urbanelli L, Magini A, Ciccarone V, Trivelli F, Polidoro M, Tancini B, Emiliani C. New perspectives for the diagnosis of Alzheimer's disease. Recent Pat CNS Drug Discov 4: 160-181 (2009).
8. Selkoe DJ. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 192: 106-113 (2008).
9. Glabe CG. Structural classification of toxic amyloid oligomers. J Biol Chem 283: 29639-43(2008).
10. Walsh DM, Selkoe DJ. A beta oligomers: a decade of discovery. J Neurochem 101: 1172-84 (2007).
11. Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 8: 57-69 (2007).
12. Ferretti MT, Bruno MA, Ducatenzeiler A, Klein WL, Cuello AC. Intracellular Aβ-oligomers and early inflammation in a model of Alzheimer's disease. Neurobiol Aging 33: 1329-42 (2012).
13. Buchhave P, Zetterberg H, Blennow K, Minthon L, Janciauskiene S, Hansson O. Soluble TNF receptors are associated with Aβ metabolism and conversion to dementia in subjects with mild cognitive impairment. Neurobiol Aging 31: 1877-84 (2010).
14. Sutcliffe JG, Hedlund PB, Thomas EA, Bloom FE, Hilbush BS. Peripheral reduction of β-amyloid is sufficient to reduce brain β-amyloid: implications for Alzheimer's disease. J Neurosci Res 89: 808-14(2011).
15. Sagare AP, Bell RD, Zlokovic BV. Neurovascular defects and faulty amyloid-β vascular clearance in Alzheimer's disease. J Alzheimers Dis 33: S87-100 (2013).
16. Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E, et al. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging 31: 357-67 (2010).
17. Schupf N, Zigman WB, Tang MX, Pang D, Mayeux R, Mehta P, et al. Change in plasma Aβ peptides and onset of dementia in adults with Down syndrome. Neurology 75: 1639-44 (2010).
18. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-44 (1984).
19. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56: 303-08 (1999).
20. Xia W, Yang T, Shankar G, Smith IM, Shen Y, Walsh DM, et al. A specific enzyme-linked immunosorbent assay for measuring betaamyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol 66: 190-99 (2009).
21. Tsai MS, Tangalos EG, Petersen RC, Smith GE, Schaid DJ, Kokmen E, et al. Apolipoprotein E: risk factor for Alzheimer disease. Am J Hum Genet 54: 643-49 (1994).
22. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440: 352-57 (2006).
23. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 8: 79-84 (2005).
24. Dahlgren KN, Manelli AM, Stine WB, Baker LK, Krafft GA, LaDu MJ. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 277: 32046-53 (2002).
25. Pan XD, Zhu YG, Lin N, Zhang J, Ye QY, Huang HP, et al. Microglial phagocytosis induced by fibrillar β-amyloid is attenuated by oligomeric β-amyloid: implications for Alzheimer's disease. Mol Neurodegener 6: 45 (2011).
26. Grimmer T, Henriksen G, Wester HJ, Forstl H, Klunk WE, Mathis CA, et al. Clinical severity of Alzheimer's disease is associated with PIB uptake in PET. Neurobiol Aging 30: 1902-09 (2008).
27. Jack CR Jr. Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 131: 665-680 (2009).
28. Fripp J, Bourgeat P, Acosta O, Raniga P, Modat M, Pike KE, et al. Appearance modeling of 11C PiB PET images: characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging. Neuroimage 43: 430-39 (2008).
29. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer disease. Am J Pathol 155: 853-862 (1999).
30. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, et al. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer disease. Ann Neurol 46: 860-866 (1999).
31. Pitschke M, Prior R, Haupt M, Riesner D. Detection of single amyloid beta protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy. Nat Med 4: 832-834 (1998).
32. Santos AN, Simm A, Holthoff V, Boehm G. A method for the detection of amyloid-beta1-40, amyloid-beta1-42 and amyloid-beta oligomers in blood using magnetic beads in combination with flow cytometry and its application in the diagnostics of Alzheimer's disease. J Alzheimers Dis 14: 127-131 (2008).
33. Zhou L, Chan KH, Chu LW, Kwan JS, Song YQ, Chen LH, et al. Plasma amyloid-β oligomers level is a biomarker for Alzheimer's disease diagnosis. Biochem Biophys Res Commun 423: 697-02 (2012).
34. Tamaoka A, Fukushima T, Sawamura N, Ishikawa K, Oguni E, Komatsuzaki Y, et al. Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease. J Neurol Sci 141: 65-68 (1996).
35. Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol 60: 958-964 (2003).
36. Shen Y, He P, Zhong Z, McAllister C, Lindholm K. Distinct destructive signal pathways of neuronal death in Alzheimer's disease. Trends Mol Med 12: 574-79(2006).
37. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 10: 45-65(2003).
38. Bai L, Song N, Yu J, Tan L, Shen Y, Xie J, et al. Elevated plasma levels of soluble TNFRs and TACEactivity in Alzheimer's disease patients of Northern Han Chinese descent. Curr Alzheimer Res 10: 57-62 (2013).
39. Ferretti MT, Bruno MA, Ducatenzeiler A, Klein WL, Cuello AC. Intracellular Aβ-oligomers and early inflammation in a model of Alzheimer's disease. Neurobiol Aging 33: 1329-42 (2012).
40. Pan XD, Chen XC, Zhu YG, Chen LM. Zhang J, Huang TW, et al. Tripchlorolide protects neuronal cells from microglia mediated beta-amyloid neurotoxicity through inhibiting NF-kappaB and JNK signaling. Glia 57: 122738 (2009).
41. He Y, Zheng MM, Ma Y, Han XJ, Ma XQ, Qu CQ, et al. Soluble oligomers and fibrillar species of amyloid β-peptide differentially affect cognitive functions and hippocampal inflammatory response. Biochem Biophys Res Commun 429: 125-30 (2012).
42. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurology 2: 605-13(2003).
43. Gao CM, Yam AY, Wang X, Magdangal E, Salisbury C, Peretz D, et al. Abeta40 oligomers identified as a potential biomarker for the diagnosis of Alzheimer's disease. PLoS One 5: e15725 (2010).